Skip to main content
Wolfson Institute of Population Health

Dr Judith Offman


Senior Lecturer in Cancer Prevention and Early Detection



I joined the Centre for Cancer Screening, Prevention and Early Diagnosis at the Wolfson Institute of Population Health in 2022, where I was appointed as a Senior Lecturer in Cancer Prevention and Early Detection. I am a cancer epidemiologist with prior training as a molecular biologist. I am also a Visiting Senior Lecturer at King’s College London, where I worked from 2018-2022.

I am a co-investigator on the £5m NIHR Policy Research Unit (PRU) on Cancer Awareness, Screening and Early Diagnosis, led by Professor Stephen Duffy. I am also a co-investigator on the Cancer Research UK (CRUK) and Asthma UK and British Lung Foundation funded Machine Learning for Discovery of Pre-neoplastic signature in Mesothelioma (PRISM) project.

In the past I had leading roles on clinical trials in breast cancer screening and the now completed BEST3 (Barrett’s oESophagus Trial 3) trial in early detection of Barrett’s oesophagus. I am currently the trial statistician on several prospective prostate cancer screening studies including the IMPACT study (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in men at higher genetic risk and controls).

I collaborate with academics, researchers, and healthcare professionals nationally and internationally, including from CRUK, King’s College London, Imperial College London, University of Warwick, National Cancer Institute (USA), and International Agency for Research on Cancer (IARC). I furthermore actively work with patients and the public in designing, carrying out and disseminating research. I also collaborate with industry on new diagnostic tools for cancer.


Research Interests:

The aim of my research is to identify ways to prevent cancer altogether or to diagnose it early when it is easier to treat successfully. The core of my research interest therefore comprises, firstly, the identification of individuals at high risk for developing cancer, so that these patients can be tested, and, secondly, the diagnosis of pre-cancerous lesions, so that these can be removed or patients can undergo regular surveillance. My research focuses mainly on oesophageal cancer (OC) and malignant pleural mesothelioma (MPM), but I have also been involved in research on breast cancer screening. I am particularly interested in the use of new diagnostic tools, including machine learning models, in early cancer detection.

My research expertise covers both observational and experimental epidemiology and includes cohort studies and randomised controlled trials. I am particularly interested in study design and I use mixed methods, including patient engagement, to optimise clinical trial design. Furthermore, I also have a strong interest in cancer risk factors and their impact patient outcomes. Lastly, I also have extensive experience working with large datasets from primary and secondary care and other health datasets.


Please follow through to see complete list of Judith's publications.

Eastwood, M., Marc, S. T., Gao, X., Sailem, H., Offman, J., Karteris, E., Fernandez, A. M., Jonigk, D., Cookson, W., Moffatt, M., Popat, S., Minhas, F., Robertus, J. L. Malignant Mesothelioma Subtyping of Tissue Images via Sampling Driven Multiple Instance Prediction. (2022). In: Michalowski, M., Abidi, S.S.R., Abidi, S. (eds) Artificial Intelligence in Medicine. AIME 2022. Lecture Notes in Computer Science(), vol 13263. Springer, Cham.

Maroni, R., Barnes, J., Offman, J. (joint first authors), Scheibl, F., Smith, S.G., Debiram-Beecham, I., Waller, J., Sasieni, P.D., Fitzgerald, F.G., Rubin, G., BEST3 Consortium, Walter, F.M. Patient-reported experiences and views on the Cytosponge test: a mixed-methods analysis from the BEST3 trial. BMJ Open. 2022; 12: e054258.

Offman, J., Pesola, F. (joint first author), Fitzgerald, R.C., Hamilton, W., Sasieni, P. Impact of Barrett esophagus diagnoses and endoscopies on esophageal cancer survival in the UK: a cohort study. Cancer Medicine. 2022; 11:1160-71.

Fitzgerald, R., di Pietro, M., O’Donavan, M., Maroni, R., Muldrew, B., Debiram-Beecham, I., Gehrung, M., Offman, J., et al. A Randomised, Controlled Trial of an offer of Cytosponge-TFF3 test compared with usual care to identify Barrett’s oesophagus in primary care. The Lancet. 2020, 396(10247):333-344.

Offman, J., Pesola, F., Sasieni, P. Trends and projections in adenocarcinoma and squamous cell carcinoma of the oesophagus in England from 1971 to 2037. British Journal of Cancer. 2018; 118(10):1391-1398.


Amy Tickle, Cancer Research UK, "Indicators of progress towards reducing cancer mortality through early diagnosis".

Soumya Arun, Barts Charity, "Evaluation of validations of artificial intelligence modalities for digital pathology-based diagnosis of lung cancer: a systematic review". (Start Date: Dec 2021)


Back to top